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One of the most important factors behind resistance evolution in malaria is the failure to deliver 
sufficiently high amounts of drugs to early stages of Plasmodium-infected red blood cells (pRBCs). 
Despite having been considered for decades as a promising approach, the delivery of antimalarials 
encapsulated in immunoliposomes targeted to pRBCs has not progressed towards clinical 
applications, whereas in vitro assays rarely reach drug efficacy improvements above 10-fold. Here 
we show that encapsulation efficiencies reaching >96% are achieved for the weak basic drugs 
chloroquine (CQ) and primaquine using the pH gradient loading method in liposomes containing 
neutral saturated phospholipids. Targeting antibodies are best conjugated through their primary 
amino groups, adjusting chemical crosslinker concentration to retain significant antigen recognition.
Antigens from non-parasitized RBCs have also been considered as targets for the delivery to the 
cell of drugs not affecting the erythrocytic metabolism. Using this strategy, we have achieved 
unprecedented complete nanocarrier targeting to early intraerythrocytic stages of the malaria 
parasite for which there is a lack of specific extracellular molecular tags. Immunoliposomes studded
with monoclonal antibodies raised against the erythrocyte surface protein glycophorin A were 
capable of targeting 100% RBCs and pRBCs at the low concentration of 0.5 µM total lipid in the 
culture, with >95% of added liposomes retained on cell surfaces. When exposed for only 15 min to 
Plasmodium falciparum in vitro cultures of early stages, free CQ had no significant effect on the 
viability of the parasite up to 200 nM, whereas immunoliposomal 50 nM CQ completely arrested its
growth. In vivo assays in mice showed that immunoliposomes cleared the pathogen below 
detectable levels at a CQ dose of 0.5 mg/kg, whereas free CQ administered at 1.75 mg/kg was, at 
most, 40-fold less efficient. Our data suggest that this significant improvement is in part due to a 
prophylactic effect of CQ found by the pathogen in its host cell right at the very moment of 
invasion.
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1. Introduction
The majority of chemotherapeutic approaches against malaria are targeted at the Plasmodium 
stages infecting red blood cells (RBCs), which are responsible for all symptoms and pathologies of 
the disease [1]. Because of the amphiphilicity of most current antimalarial drugs, they are 
extensively distributed into body tissues after administration and can be rapidly metabolized in the 
liver [2]. In the blood vessels, antimalarial drugs circulate mainly associated to plasma proteins [3] 
and are usually quickly removed from circulation, presenting relatively short half-lives from less 
than one hour to few hours [2]. These shortcomings are usually compensated through administration
of increased doses, in a delicate narrow edge between high overall amounts causing toxic side 
effects [4] and low local concentrations inducing resistance evolution in most malaria-endemic 
countries [5].
Drugs specifically targeted to parasitized RBCs (pRBCs) would benefit from a reduction in 
the body distribution volume, lasting longer in the bloodstream while avoiding degradation, and 
increasing exposure of the pathogen to lethal doses. Liposomal nanovectors bearing cell-specific 
antibodies on their surfaces (immunoliposomes, iLPs) have been widely considered as 
chemotherapeutic drug carriers due to their non-toxic and biodegradable character [6], but they have
not progressed yet towards a working strategy for malaria therapeutics. Pioneering assays to treat 
Plasmodium berghei infections in mice focused on the encapsulation of the antimalarial drug 
chloroquine into liposomes (LPs) and iLPs functionalized with antibodies against RBCs and pRBCs
[7-9]. Drug efficacy was significantly improved upon encapsulation, especially when targeted 
towards pRBCs, and after treatment with iLPs, mice exhibited lower parasitemias and longer 
survival times even with drug-resistant strains. These improvements were attributed to the specific 
interaction of targeting antibodies with RBCs/pRBCs and to the efficient incorporation of LP 
contents into the cells, although liposomal models were poorly characterized with no direct 
evidence for LP internalization and absence of encapsulated drug stability and release kinetics 
analyses. Moreover, because all these studies were done in murine malarias, there was a lack of data
for human-infecting parasites, particularly for the deadliest species, Plasmodium falciparum.
Recently, in vitro assays in P. falciparum have shown that LPs functionalized with pRBC-
specific antibodies can specifically recognize target cells vs. non-infected erythrocytes in less than 
90 min [10]. The short time required to achieve complete specificity was an encouraging result that 
opened good perspectives regarding the development of a rapid delivery nanovector capable of 
competing with LP clearance from blood by macrophages and the liver [11]. Nevertheless, this good
targeting has not been able to provide improvements in drug efficacy above 10-fold [12], and 
parasitemia could not be completely eliminated from the cultures. In vivo assays in mice grafted 
with human erythrocytes and subsequently infected with P. falciparum [13] showed that some iLP-
encapsulated antimalarials had a clearly improved efficacy (Fig. 1A). However, as in in vitro assays,
Plasmodium parasites could not be completely cleared despite the continuous presence of iLPs in 
the blood of mice during the entire length of four-day tests (Fig. 1B).
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Fig. 1. (A) 4-day test in female immunodeficient mice engrafted with human erythrocytes and infected i.v. 
with P. falciparum. The different curves correspond to drug-containing iLPs functionalized with the pRBC-
specific antibody BM1234 as previously described [10]. (a) and (b) correspond to artesunate-containing iLPs 
where the drug was added, respectively, to the lipid mixture before evaporation of the solvent, or to the 
aqueous buffer added to the dry lipids to form LPs. (B) Residence time in the bloodstream of mice of 
rhodamine-labeled LPs with the same lipid composition as in (A).
Often, the particularities of malaria pathophysiology have not been sufficiently considered 
when designing iLPs for targeted antimalarial drug delivery. Most drugs used in the treatment of 
malaria are amphiphilic compounds whose capacity to solubilize in both aqueous and organic 
phases allows them to easily cross lipid bilayers, which complicates their liposomal encapsulation. 
Therefore, special liposome formulations including saturated long-chain phospholipids with 
elevated phase transition temperatures (>37 °C) together with low amounts of cholesterol are 
crucial components required to avoid the otherwise quick leakage of small molecules [14]. In 
addition, since lipid bilayers are highly impermeable to ionized species, working at the adequate pH
is paramount to sustain a proton gradient and attain higher liposomal drug loads. Other factors to be 
taken into account are the nature, location, and abundance of markers on pRBC surfaces: although 
Plasmodium proteins are found in the plasma membrane of pRBCs [15], those currently known are 
highly variable or have a low abundance [16]. Given this scarcity of adequate antigens exposed on 
pRBCs, essential parameters that will be determinant in the capacity of iLPs to recognize and bind 
target cells are a careful selection of sufficiently specific antibodies, the way they are crosslinked to 
lipids, and their numbers on the liposome surface. Since RBCs have very poor endocytic processes 
[17], once iLPs are docked to them delivery of cargo into the cell has been proposed to occur 
through a membrane fusion process [7,10,18,19]. Nevertheless, considering the lack of strong 
evidence and the poor characterization of this fusion process using RBCs and pRBCs as targeted 
cells, alternative mechanisms of interaction should be considered. These include, but are not limited
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to, the stable adsorption on the target cell surface or the entry through the tubulovesicular network 
(TVN) [17] and other modifications suffered by erythrocyte membranes when the cell has been 
parasitized by Plasmodium.
Here we have dissected the different iLP parts to propose a rational design strategy for the 
administration of lethal amounts of drugs to the intraerythrocytic pathogen. The results presented 
can significantly contribute to developing new and optimized targeted drug delivery approaches 
against malaria based on a dual and simultaneous (i) therapeutic activity on pRBCs and (ii) 
prophylactic effect against erythrocyte infection by Plasmodium.
2. Materials and methods
2.1. Materials
Except where otherwise indicated, reactions were performed at room temperature (20 °C), and
reagents were purchased from Sigma-Aldrich Corporation (St. Louis, MO, USA). The lipids (all 
≥99% purity according to thin layer chromatography analysis) 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine-N-[4-(p-maleimidophenyl)butyramide] (MPB-PE), 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (DSPE-PEG2000-
Mal), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[lissamine rhodamine B sulfonyl] (DOPE-
Rho), and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]
(PE-PEG2000) were purchased from Avanti Polar Lipids Inc. (Alabaster, AL, USA). Mouse 
monoclonal IgG anti-human GPA SM3141P, rabbit polyclonal IgG anti-human GPA AP05437PU-N,
mouse monoclonal anti-HRP2 AM01200PU-N, and mouse monoclonal IgM BM1234 were 
purchased from Acris Antibodies, Herford, Germany.
2.2. Preparation of LPs and encapsulation of drugs
LPs with a basic formulation of neutrally charged unsaturated (DOPC:cholesterol, 80:20) or 
saturated (DSPC:cholesterol, 90:10) phospholipids were prepared by the lipid film hydration 
method [20]. Briefly, stock lipids in chloroform were mixed and dissolved in chloroform:methanol 
(2:1, v/v) in a round-bottomed flask. Organic solvents were removed by rotary evaporation under 
reduced pressure at 37 °C, in a progressive vacuum range from 20 to 70 mmHg, to yield a thin ‒ ‒
lipid film on the flask bottom and walls. For passive drug encapsulation, the dried lipids were then 
hydrated to 10 mM total lipid in 10 mM phosphate buffer, pH 6.5, containing the desired 
drug/molecule to encapsulate and osmotically adjusted to 320 mOsm/kg (isotonic with P. 
falciparum growth medium) by addition of 5 M NaCl. Multilamellar LPs were formed by 3 cycles 
of constant vortexing followed by bath sonication for 3 minutes each, and downsized to unilamellar 
vesicles by extrusion through 200 nm polycarbonate membranes (Poretics, Livermore, CA, USA) in
an extruder device (LiposoFast, Avestin, Ottawa, Canada). Throughout the lipid film hydration and 
downsizing processes samples were maintained above lipid transition temperature. LP size was 
determined by dynamic light scattering using a Zetasizer NanoZS90 (Malvern Ltd, Malvern, UK). 
Unencapsulated material was removed by buffer exchange in 7-kDa Zeba™ spin desalting columns 
(Thermo Fisher Scientific, Inc.) using isotonic phosphate buffered saline (PBS) at the desired pH 
(7.5 unless otherwise indicated). Finally, liposomal suspensions to be used in assays with live cells 
were sterile filtered through 0.22 µm pore size polyvinylidene difluoride (PVDF) filters (Millex-GV
Syringe Filter Units, 4 mm, Millipore). Active encapsulation by the pH gradient method was done 
following an adaptation of established protocols [21], substituting saturated DSPC for unsaturated 
DOPC to obtain a lipid bilayer capable of sustaining a proton gradient. LPs were prepared in 200 
mM citrate buffer at pH 4.0 and buffer exchanged with isotonic PBS containing 10 mM 
ethylenediaminetetraacetic acid (EDTA) in order to establish a pH gradient across the LP 
membrane. One volume of drug was then mixed with ten volumes of LPs to reach final 
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concentrations of 500 µM chloroquine (CQ) and 1 mM primaquine (PQ) and the mixture was 
stirred for 30 min at room temperature before immediately proceeding, when required, to antibody 
coupling.
2.3. Generation of polyclonal antibodies against MAHRP121-40 peptide
MAHRP121-40 (ADVPTEGMDVPFGFFDKNTL) was synthesized (Peptide Synthesis Service,
Scientific and Technological Centers, University of Barcelona) with an additional cysteine at the 
carboxy terminal end. Immunization of rabbits was done at the facilities of the Animal 
Experimentation Services (University of Barcelona) following standard protocols. Serum antibodies
were purified by affinity chromatography using the corresponding peptides immobilized on agarose 
beads (SulfoLink Kit, Pierce Biotechnology, Rockford, IL, USA), assayed by Enzyme-Linked 
ImmunoSorbent Assay (ELISA), and finally stored at 20 °C.‒
2.4. Generation of iLPs
Freshly prepared maleimide-containing LPs were conjugated with thiolated antibodies 
following established protocols [22]. The generation of sulfhydryl groups in antibodies was 
performed through three alternative approaches: (i) Half-antibodies bearing free thiols generated by 
reduction with 2-mercaptoethylamine-HCl (MEA, Thermo Fisher Scientific, Inc.) were obtained as 
described previously [10]. (ii) Reactive aldehyde groups (CHO) were generated in the carbohydrate 
moieties of antibody (Ab) Fc regions by oxidation in PBS containing 5 mM sodium periodate (1 h, 
protected from light) [23]. Oxidized antibodies were then recovered by buffer exchange in PBS, pH 
7.2, and conjugated by hydrazone linkage through a 2-h incubation with a 150-fold molar excess of 
freshly dissolved 3-(2-pyridyldithio)propionyl hydrazide crosslinker (PDPH, Thermo Fisher 
Scientific, Inc.). The number of reactive aldehyde groups available (ca. 2/Ab) was quantified before
PDPH conjugation by incubation of oxidized antibodies with Lucifer Yellow CH fluorescent dye, as
described previously [24]. Excess of crosslinker was removed by buffer exchange in SAS buffer 
(100 mM sodium acetate, 50 mM NaCl, pH 4.4) and thiol groups were finally exposed through 
pyridyldithiol group cleavage by addition of 25 mM dithiothreitol (DTT) and incubation for 20 min.
(iii) For the non-oriented binding through primary amino groups, antibodies in PBS were reacted 
for 30 min with a 10 to 100 molar excess relative to antibody molecules of the crosslinker N-
succinimidyl S-acetylthioacetate (SATA, Thermo Fisher Scientific, Inc.) freshly dissolved in 
dimethyl sulfoxide. Unreacted SATA was removed by buffer exchange in PBS and protected thiols 
in SATA-conjugated antibodies were exposed by addition of 50 mM hydroxylamine and 2.5 mM 
EDTA. After thiolation, antibodies were recovered by buffer exchange in PBS supplemented with 
10 mM EDTA and the number of available sulfhydryl groups was determined by reaction with 5,5'-
dithio-bis-(2-nitrobenzoic acid) (DTNB, Thermo Fisher Scientific, Inc.). 400 µg DTNB/ml were 
added to the thiolated antibody solution, and after 20 min the formation of 2-nitro-5-thiobenzoic 
acid was quantified by measuring its absorbance at 412 nm. Finally, coupling of freshly thiolated 
antibodies to freshly prepared maleimide-containing LPs was done overnight (12 to 15 h) in PBS 
supplemented with 10 mM EDTA. Unbound antibodies were removed by ultracentrifugation 
(150,000 g, 1 h, 4 °C), maintaining the same tonicity and LP concentration (10 mM lipid) during the
whole process. For the intercalation of a polyethylene glycol (PEG) linker between LP and 
antibody, DSPE-PEG2000-Mal was substituted for MPB-PE in the LP formulation. Pelleted iLPs 
were taken up in PBS and stored at 4 °C for up to one month before being used. Antibody coupling 
was quantitatively assessed by protein determination with the DC™ Protein Assay (Bio-Rad). 
Coupling efficiency (%) was determined as the fraction of LP-bound antibody relative to total 
antibody added; the number of bound antibodies per LP was determined considering an IgG 
molecular mass of 150 kDa and the theoretical lipid content of a LP 170 nm in diameter composed 
solely of phosphatidylcholine [25]. For qualitative SDS-polyacrylamide gel electrophoresis (PAGE)
coupling analysis, supernatant and pelleted iLP samples were heated at 90 °C for 3 min in 1 
5
Laemmli sample buffer, supplemented with 355 mM 2-mercaptoethanol, and electrophoresed in 
7.5% SDS-polyacrylamide gels using the Mini Protean II System (Bio-Rad). For silver staining of 
gels [26], they were fixed (40% ethanol, 10% acetic acid) during 30 min and activated (30% 
ethanol, 41 mg/ml sodium acetate, 1.27 mg/ml sodium thiosulfate) for 30 min. After washing with 
deionized water (Milli-Q system, Millipore), gels were stained (1 mg/ml silver nitrate, 0.02% 
formaldehyde) for 40 min and protein bands were developed (25 mg/ml sodium carbonate, freshly 
prepared 0.01% formaldehyde). Finally, the reaction was terminated by addition of 1% acetic acid 
and gels were stored in 10% glycerol solution.
2.5. Quantification of drugs and fluorescent dyes in LP samples
Encapsulated CQ and PQ were quantified by measuring their respective absorbances at 342 
and 352 nm after LP (0.5 mM lipid) disruption by treatment with 2% v/v Triton X-100 in PBS, 
subtracting the lecture of drug-free LPs. Encapsulated fluorescent dye quantification was performed
by fluorescence analysis (Synergy HT Multi-Mode Microplate Reader, BioTEK) of pyranine (λex/em 
= 488/520 nm), and of rhodamine-conjugated lipid (DOPE-Rho; λex/em = 530/590 nm). 
Encapsulation efficiency (EE, %) represents the encapsulated fraction relative to total compound 
added to the LP-containing solution. High performance liquid chromatography-tandem mass 
spectrometry (HPLC-MS/MS) was used to quantify CQ concentrations below the detection limit of 
UV-Vis spectroscopy (20 nM and 2 µM CQ detection limits for HPLC-MS/MS and UV-Vis 
spectroscopy, respectively), according to established protocols [12]. The release rate from LPs of 
encapsulated CQ and PQ was determined at selected time points by drug quantification in the 
supernatants and corresponding pelleted LPs obtained after ultracentrifugation (100,000 g, 45 min, 
4 °C). Release rates were expressed as the percentage of drug in the supernatant relative to the total 
drug present in the sample. All experimental values are represented as mean ± SD for 3 replicates.
2.6. P. falciparum in vitro culture and growth inhibition assays
P. falciparum strain 3D7 was grown in vitro in group B human erythrocytes using previously 
described conditions [27]. Parasites (thawed from glycerol stocks) were cultured at 37 °C in Petri 
dishes with RBCs at 3% hematocrit in Roswell Park Memorial Institute (RPMI) complete medium 
containing Albumax II (RPMI-A, Invitrogen), supplemented with 2 mM L-Glutamine, under a gas 
mixture of 92% N2, 5% CO2, and 3% O2. Synchronized cultures in early ring stages (0-24 h post-
invasion) were obtained by 5% sorbitol lysis [28]. Late-form trophozoite and schizont stages (24-36
h and 36-48 h post-invasion, respectively) were purified in 70% Percoll (GE Healthcare) [28,29]. 
Parasitemia was determined by microscopic counting of blood smears fixed briefly with methanol 
and stained with Giemsa (Merck Chemicals) diluted 1:10 in Sorenson’s buffer, pH 7.2, for 10 min. 
For culture maintenance, parasitemia was kept below 5% late forms and 10% early forms by 
dilution with freshly washed RBCs and the medium was changed every 1-2 days. For P. falciparum 
in vitro growth inhibition assays, cultures synchronized (>95%) in early ring or late form stages 
were brought to 4% hematocrit and 1% parasitemia by dilution with fresh RBCs. After adding one 
culture volume of 2 concentrated drug solution in RPMI-A, cultures were incubated for 15 min in 
2-ml Petri dishes under orbital stirring, transferred to microcentrifuge tubes, and cells were spun 
down, finally replacing the medium with fresh RPMI-A. Unless otherwise specified, the data 
presented throughout the manuscript refer to samples containing 2% hematocrit. The resulting cell 
suspension was then seeded on 96-well plates (Merck Chemicals) and further incubated for a 
complete 48-h growth cycle under the conditions described above. For growth inhibition 
determination, samples were diluted 1:100 in PBS, and the nuclei of pRBCs (the only nucleated 
cells present in the culture) were stained by addition of 0.1 μM Syto11 (Thermo Fisher Scientific, 
Inc.) in the final mixture before proceeding to flow cytometry analysis.
2.7. Protein expression analysis throughout the 48-h intraerythrocytic cycle
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For the analysis of MAHRP-1 (BM1234 antigen) and HRP2 protein expression throughout the
whole intraerythrocytic cycle of P. falciparum, tightly synchronized cultures (0-5 h range, 8% 
parasitemia) were obtained using a combination of 70% Percoll and 5% sorbitol (5 h after release of
merozoites) stage-selection methods as described above. Culture samples corresponding to 3 µl 
pRBCs were obtained at the following post-infection timepoints: 12 h, 20 h (rings); 26 h, 35 h, 38 h 
(trophozoites); 42 h, 44 h and 46 h (schizonts). Protein expression was analyzed by subcellular 
detergent fractionation (see below) and SDS-PAGE/Western blot, as previously described [10], 
using the primary monoclonal antibodies BM1234 (2 µg/ml) and anti-HRP2 (0.5 µg/ml), and as 
secondary antibody goat anti-mouse IgG horseradish peroxidase-conjugated (1 µg/ml, Thermo 
Fisher Scientific, Inc.).
2.8. Fluorescence microscopy
Antigen localization in fixed cells by fluorescence confocal microscopy was done according 
to established protocols [10]. Briefly, air-dried blood smears were fixed in 1% formaldehyde and 
cell membranes were labeled with 3.3 µg/ml wheat germ agglutinin-tetramethylrhodamine (WGA-
Rho) conjugate (Molecular Probes, Eugene, OR, USA). Slides were then incubated in the presence 
of 20 µg/ml of the mouse monoclonal antibodies BM1234 or anti-HRP2, and the rabbit polyclonal 
antibodies anti-PfEMP1 (raised against the conserved C-terminal domain, gently provided by Dr. 
Alfred Cortés) and MAHRP121-40, followed by incubation in the presence of 6.7 µg/ml of the 
corresponding Alexa Fluor® secondary antibodies goat anti-mouse AF488 or AF660, or goat anti-
rabbit AF488 (all from Molecular Probes), and of 1 µg/ml 4′ 6-diamino-2-phenylindole (DAPI, 
Invitrogen) for nuclei staining. All antibody treatments were done for 1 h in the presence of 0.75% 
w/v bovine serum albumin as blocking agent. Finally, slides were washed with PBS, mounted with 
ProLong® Gold antifade reagent (Molecular Probes), and examined with a Leica TCS SP5 laser 
scanning confocal microscope as described [10]. 
For immunofluorescence assays with live cells of the targeting efficiency of free antibodies 
and iLPs, P. falciparum cultures at 5% parasitemia were washed 3 with RPMI-A (700 g, 2 min) 
and nuclei were stained for 30 min with 2 µg/ml Hoechst 33342 (Molecular Probes). Excess dye 
was removed by washing cells 3 with RPMI-A and hematocrit was lowered to 2.5% trough RPMI-
A addition. Four volumes of this culture were then added to 1 vol of antibody- or iLP-containing 
samples to reach, respectively, 70 µg antibody/ml or 1 mM lipid, and 2% hematocrit, and samples 
were incubated for 1.5 h at 37 °C under orbital mixing. When using the free monoclonal antibody 
anti-GPA, its concentration was lowered to 1 µg/ml because of excessive RBC agglutination found 
at higher concentrations, with no significant difference in targeting. iLPs loaded with the fluorescent
dye pyranine were observed directly, whereas antibodies were detected with the corresponding 
fluorescent secondary antibodies as described above, but diluted in RPMI-A. Finally, cells were 
washed 3 with RPMI-A and placed at 0.2% hematocrit into MatTek culture plates for further 
analysis with an Olympus IX51 inverted system microscope, equipped with an IX2-SFR X-Y stage,
a U-TVIX-2 camera, and a fluorescence mirror unit cassette for UV/blue/green excitation and 
detection of their respective blue/green/red emission ranges. Phase contrast images were acquired 
simultaneously.
2.9. Flow cytometry
For growth inhibition determination and quantitative live cell targeting examination of 
antibodies and iLPs, samples were analyzed at 0.02% hematocrit in PBS with a BD LSRFortessa 
flow cytometer (Becton, Dickinson and Company, New Jersey, USA). Forward- and side-scatter in 
a logarithmic scale were used to gate the RBC population. Green fluorescent dyes (Syto11, 
pyranine, and AF488) and Hoechst 33342 were detected, respectively, by excitation through a 488 
7
or 355 nm laser at 50 mW power and emission collection with a 530/30 or 450/50 nm bandpass 
filter. Acquisition was configured to stop after recording 20,000 events within the RBC population. 
Parasitized erythrocytes in late forms were distinguished from those in young forms, when required,
by means of their increased DNA and RNA content giving higher Syto11 signal intensity values.
2.10. Transmission electron microscopy (TEM)
P. falciparum cultures sorbitol-synchronized at ring, trophozoite, and schizont stages were 
washed 3 with PBS (470 g, 5 min), and 6-µl volumes of pelleted cells were fixed in 500 µl of 4% 
v/v formaldehyde in PBS for 1 h at 4 °C under orbital stirring. The fixing solution was changed to 
2% v/v formaldehyde in PBS and cells were left in the same solution at 4 °C for 24 h until gelatine 
embedding. Prior to fixation, ring samples were at 10% parasitemia, whereas trophozoite and 
schizont stages were enriched to >90% parasitemia in 70% Percoll. After fixation, sample 
processing for the preparation of ultrathin cryosections was done as previously described [30]. 
Cryosections were incubated for 30 min in PBS containing 5% fetal bovine serum with the 
corresponding primary antibodies (mouse BM1234, anti-HRP2 and anti-GPA at 40 µg/ml, and 
rabbit anti-MAHRP121-40 at 21 µg/ml), followed by secondary antibodies (50 µg/ml goat anti-mouse
or goat anti-rabbit IgG H+L) coupled to 12-nm colloidal gold particles (Jackson ImmunoResearch 
Laboratories Inc., West Grove, PA, USA). As control for non-specific secondary antibody binding 
the primary antibody was omitted; non-infected red blood cells were also processed as a control for 
non-specific interactions of the primary antibodies. Sample observations were done in an electron 
microscope Jeol J1010 (Jeol, Japan) with a CCD SIS Megaview III camera.
For immunocryo-TEM analysis of anti-GPA targeted LPs, a thin aqueous film was formed by 
dipping a glow discharged holey carbon grid in the LP suspension and then blotting the grid against 
filter paper. The resulting thin sample films spanning the grid holes were then incubated with a 1:20
v/v dilution of goat anti-mouse IgG (H+L) antibody coupled to 6-nm colloidal gold particles 
(Jackson ImmunoResearch Laboratories Inc.) for 30 min and washed twice in PBS. Sample 
vitrification and microscope analysis were done as described previously [10].
2.11. Subcellular protein fractionation
Differential detergent fractionation of pRBC proteins was essentially performed as previously 
described [31]. PBS supplemented with 1 complete protease inhibitor cocktail (Roche) was used 
for the washing of cells and as buffer for all detergent-containing samples; all fractions were 
obtained using the same detergent extraction volume, calculated as 6 pRBC pellet starting volume.
Cells were extensively washed and extracted with 0.15% saponin for 10 min at 4 °C, pelleted by 
centrifugation (10,000 g, 15 min, 4 °C), and the resulting supernatant was rescued as the saponin-
soluble fraction. The saponin-insoluble pellet was washed again before being extracted with 1% 
Triton X-100 (30 min, 4 °C). Samples were centrifuged (20,000 g, 30 min, 4 °C) and the resulting 
supernatant was rescued as the Triton-soluble fraction. Finally, the Triton-insoluble pellet was 
washed again before the final extraction with 2 SDS-containing reducing Laemmli sample buffer 
(supplemented with 355 mM 2-mercaptoethanol) for 30 min at 60 °C while vigorously mixing by 
vortex every 10 min. The final SDS-soluble fraction was then collected after spinning down cell 
debris (16,000 g, 15 min). For two-dimensional-PAGE, the Triton-insoluble pellet was extracted 
with O’Farrell lysis buffer (5% v/v 2-mercaptoethanol, 2% w/v NP-40, 9.5 M urea) [32] for 30 min 
at 30 °C under sonication (30-second pulses, 100% amplitude) until pellet disgregation. Saponin, 
Triton, and SDS fractions mainly contained, respectively, cytosolic proteins, membrane and 
organelle proteins, and nuclear and detergent-resistant cytoskeletal/matrix proteins. Because 
erythrocytes lack a cell nucleus and have few organelles, most of the proteins from the last two 
fractions will belong to P. falciparum.
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2.12. Two-dimensional (2D)-SDS-PAGE
To two 140-µl protein samples (containing 80 µg of total protein each) were added a trace 
amount of Bromophenol blue and an aliquot of immobilized pH gradient (IPG) buffer to reach a 
final concentration of 0.5% v/v. For the first dimension isoelectric focusing, samples were loaded 
onto two 7-cm immobilized pH gradient strips, pH 3-10 (Immobiline® DryStrip, GE Healthcare, 
Life Sciences), subjected to overnight passive rehydration (13 h, 20 °C) and then run on a IPGphor 
device (first step-and-hold, 1 h, 50 V; second step-and-hold, 0.5 h, 300 V; third gradient step 0.5 h 
to reach 1000 V; fourth gradient step, 1.5 h to reach 5000 V; and finally a fifth step-and-hold, 2.5 h, 
5000 V; the accumulated voltage was 5632 KV·h). Prior to the second dimension, the IPG strips 
were equilibrated in two steps for 15 min each with gentle shaking in 3 ml of equilibration buffer 
(first equilibration solution: 50 mM Tris-HCl, pH 8.8, 6 M urea, 30% w/v glycerol, 2% SDS, 65 
mM DTT and a trace amount of Bromophenol blue; for the second equilibration solution, DTT was 
replaced by 135 mM iodoacetamide). The second dimension SDS-PAGE was performed in a 
vertical Mini Protean Hoefer system (Hoefer, Inc.). After equilibration, strips were transferred to the
second dimension in two 12.5% polyacrylamide gels (0.375 M Tris-HCl, pH 8.8, 0.1% SDS) run for
1 h at 100 V and 20 mA/gel (running buffer: 25 mM Tris-base, 192 mM glycine, 0.1% SDS, pH 
8.6). The BenchMark™ Protein Ladder 10747-012 (Invitrogen) was run in parallel as molecular 
mass marker. One of the gels was silver-stained as described above, scanned (GS 800 Calibrated 
Densitometer M, Bio-Rad), and the image obtained was processed (Quantity One software image 
analysis, Bio-Rad). The other gel was transferred to a PVDF membrane (Hybond-P, Amersham 
Biosciences) and processed for Western blot analysis of proteins as previously described [10]. After 
incubation with the mouse monoclonal antibody BM1234 (2 µg/ml) followed by goat anti-mouse 
IgG horseradish peroxidase-conjugated (1 µg/ml, Thermo Fisher Scientific, Inc.), 
chemiluminescence was recorded (ImageQuant LAS 4000, GE Healthcare Life Sciences) and the 
membrane was finally stained with Ponceau S (0.1% w/v in 5% v/v acetic acid) for 10 min. The 
region containing the two spots detected by BM1234 was identified by triangulation using protein 
spots common to Ponceau and silver stains, excised from the silver-stained gel, and subjected to 
LC-MS/MS for protein identification.
2.13. Liquid chromatography with tandem mass spectrometry (LC-MS/MS)
Trypsin digestion of proteins in silver-stained gel slabs was performed in a ProGestTM 
automatic digestor (Genomic Solutions). Each sample was washed with 50 mM NH4HCO3 and 
acetonitrile (ACN), reduced in 10 mM DTT (30 min, 56 °C), alkylated in 55 mM iodoacetamide (30
min, 30 °C, protected from light), and digested with 80 ng of porcine trypsin (Trypsin Gold, 
Promega) for 16 h at 37 °C. The resulting peptides were extracted from the gel matrix with 5% 
formic acid (FA) and ACN, and dried in a SpeedVac concentrator. LC-MS/MS identification was 
performed in a Cap-LC-nano-ESI-Q-TOF system (Micromass-Waters). Dried peptides were taken 
up in 100 µl of 1% FA and 4-10 µl of the resulting solution was injected into the liquid 
chromatography system equipped with a reverse phase C18 column (75 µm internal diameter, 3 µm 
particle, 15 cm length; NanoEase Atlantis, Waters), with a mobile phase gradient 5-60% B in 35 
min (A: 2% ACN, 0.1% FA; B: 90% ACN, 0.1% FA). Eluted peptides were ionized trough 
electrospray (NanoES PicoTipTM emitter, New Objective) with an applied voltage of 2 KV to 
capillary/needle and 60 V to cone. A 400-1,800 m/z range of peptide masses was analyzed in full 
scan MS mode (1 s scan time, 10,000 full width at half maximum resolution). Within this range, the
10 most abundant peptides were selected (minimum intensity of 28 counts/second) for their 
fragmentation by collision-induced dissociation (20 eV collision energy, Ar gas) in the MS/MS 
analysis (1 s scan time, 100-1,700 m/z range). Peptide fragmentation generated a pkl file 
(MassLynx MS software) and sequences were matched with the NCBInr on-line database using the 
MASCOT search engine.
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2.14. Determination of LP half-life time in blood plasma
LPs fluorescently labeled and PEG-grafted (DOPC:cholesterol:DOPE-Rho:PE-PEG2000, 
64:20:1:15), were injected intravenously at 200 mg/kg doses to ICR-CD1 mice females of ca. 23 g 
(Harlan Laboratories). Blood samples of ca. 30-40 µl were then collected in Microvette heparinized 
tubes (Sarstedt) from the terminal portion of the tail at the post-administration times: t0 (2 min), 1.5 
h, 6 h, 24 h, 48 h and 72 h. Samples were separated into supernatant (plasma, stored at 80 °C until ‒
analysis) and cells by centrifugation at 4,000 g for 3 min. For fluorescence quantification of LPs 
containing the rhodamine-conjugated lipid DOPE-Rho, plasma samples were thawed on ice, diluted
with one volume of 2% Triton X-100 in PBS and 5 replicas of 2-µl drops were placed on a 
methanol-activated PVDF membrane. Fluorescence signal from spotted samples was imaged and 
analyzed with an ImageQuant LAS 4000 biomolecular imager with green RGB light source and 
1/100- to 30-s exposure time. Plasma autofluorescence signal was subtracted from samples using 
plasma collected from an untreated mouse. LP concentration was calculated by linear regression 
using serial-fold dilutions of stock LPs in PBS spotted on the same membrane at known 
concentrations. Finally, concentration values were normalized to t0 (100%) and LP half-life time 
(t1/2, time after which 50% of the administered LPs are removed from plasma), was determined.
2.15. In vivo 4-day test in P. falciparum-infected mice
Female immunodeficient NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NOD scid gamma, NSG) mice 
were engrafted with human erythrocytes and infected i.v. with the P. falciparum 3D70087/N9 strain 
generated in GlaxoSmithKline (Tres Cantos, Spain), using established methods [33]. These mice 
sustain in circulation high amounts of human RBCs (ca. 1 to 1.751010 in 2.5 ml blood). The 
inoculum was 2107 P. falciparum-infected erythrocytes, and free or encapsulated drugs were 
administered i.v. in PBS for four consecutive days starting at day 3 after infection, using 2 
mice/compound. Parasitemia was measured by flow cytometry as described [34], with 0.01% 
sensitivity of detection. Sampling was every 24 hours after start of treatment until end of assays. 
Effective dose 50% (ED50) and ED90 are defined as the dose in mg/kg that reduces parasitemia at 
day 7 after infection by 50% and 90%, respectively, relative to vehicle-treated mice. The human 
biological samples were sourced ethically and their research use was in accord with the terms of the
informed consents. All animal studies were ethically reviewed and carried out in accordance with 
European Directive 86/609/EEC and the GSK Policy on the Care, Welfare and Treatment of 
Animals.
3. Results
3.1. Passive vs. active encapsulation methods for the entrapment of antimalarial drugs into LPs
Because of their amphiphilic nature, depending on pH the weak basic antimalarial drugs 
chloroquine (CQ) and primaquine (PQ) are found in their uncharged, monoprotonated and 
diprotonated forms (Fig. 2), which have different organic/aqueous partitioning degrees. The 
encapsulation efficiencies (EEs) of CQ and PQ passively loaded through the lipid film hydration 
method [20] into LPs composed mainly of neutrally charged unsaturated phospholipids 
(DOPC:cholesterol, 80:20) were determined at different lipid film hydration solution pHs and initial
drug concentrations (Table 1). Passive EE was several-fold higher for PQ vs. CQ, which can be 
explained because of their different protonation degree. Whereas for the wide pH range 4.0-7.4 CQ 
becomes fully protonated (≥99% CQ2H+), PQ is found mainly in its monoprotonated species (≥86% 
PQH+), which confers PQ a lower ionization state and therefore higher hydrophobicity and 
interaction with the LP lipid bilayer. The significant EE increase for lower drug amounts at a fixed 
pH (Supplementary Table 1) indicates saturation of passive LP encapsulation capacity. On the other 
hand, in agreement with previous reports [21,35,36], active encapsulation of CQ and PQ by 
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establishing a pH gradient 4.0-7.5 inside-outside of LPs composed mainly of neutrally charged 
saturated phospholipids (DSPC:cholesterol, 90:10) resulted in EE values close to 100% (Table 1). 
Drug amounts during active encapsulation into LPs were selected according to the aforementioned 
works as those highest possible while avoiding a significant consumption of the internal liposomal 
proton pool.
Fig. 2. Ionization species in solution as a function of pH for the weak basic drugs chloroquine (CQ, pKas 
10.2 and 8.4 [37]) and primaquine (PQ, pKas 10.4 and 3.2 [38]). Chemical formulae were obtained from 
http://www.chemicalize.org/.
Table 1. Passive (DOPC LPs) and active (DSPC LPs) encapsulation efficiencies (EE) for CQ and PQ into 
LPs at 10 mM total lipid.
Liposomal samples Added drug(µM)
Encapsulated drug
(µM) EE (%)
DOPC CQ pH 7.4 10000 999.0 ± 5.2 10.0 ± 0.1
DOPC CQ pH 6.5 10000 499.0 ± 12.1 5.0 ± 0.1
DOPC CQ pH 6.5 25 3.5 ± 0.6 14.1 ± 2.5
DSPC CQ pH 4.0 - 7.5 500 491.7 ± 1.6 98.3 ± 0.3
DOPC PQ pH 7.4 10000 3392.6 ± 70.9 33.9 ± 0.7
DOPC PQ pH 6.5 10000 3215.0 ± 61.9 32.2 ± 0.6
DOPC PQ pH 6.5 4000 1945.9 ± 78.0 48.7 ± 2.0
DSPC PQ pH 4.0 - 7.5 1000 966.7 ± 2.1 96.7 ± 0.2
After 2 weeks in storage conditions (PBS, pH 7.4, 4 °C) insignificant release (<5 %) was 
obtained for actively encapsulated drugs (Fig. 3A). By contrast, drugs were quickly released when 
passively encapsulated, with ca. 60% and 30% of originally encapsulated CQ and PQ, respectively, 
being found outside LPs after only 5 min storage. In accordance with passive encapsulation data for
DOPC LPs (Table 1), PQ was significantly more retained than CQ (Supplementary Table 2), with 
respective encapsulated amounts at equilibrium of ca. 60% and 20%. Similar drug release results 
were obtained in P. falciparum culture conditions (PBS, pH 7.4, 37 °C, diluted samples; Fig. 3B). 
Whereas passively encapsulated CQ was almost completely released after 48 h under culture 
conditions, 30% of PQ was still retained in LPs, reflecting the higher hydrophobicity of PQ and its 
stronger lipid bilayer interaction. On the other hand, no significant release of actively encapsulated 
drug was observed under the same experimental conditions during the first 3 h of incubation, 
illustrating the capacity of the pH gradient method for amphiphilic drug containment into LPs.
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Fig. 3. Cumulative drug release of encapsulated CQ and PQ passively loaded (DOPC liposome, 10 mM drug
during encapsulation) and actively loaded (DSPC liposome, drug concentrations in Table 1) under (A) 
storage conditions (4 °C, 10 mM total lipid) and (B) culture conditions (liposomal samples in storage 
conditions further diluted 1:10 and 1:40 in PBS for CQ and PQ, respectively, and incubated at 37 °C).
3.2. Targeting antibodies against different pRBC antigens
A previous iLP prototype developed in our group was able to improve ca. 10-fold the efficacy 
of CQ in vitro [10], although most of this effect was due to liposomization of the drug, and only a 
relatively minor effect could be attributed to antibody (Ab) targeting [12]. Since the antigen of the 
pRBC-binding BM1234 commercial monoclonal antibody used was not known, we set out to 
identify it. The BM1234-positive, Triton X-100-insoluble fraction of a pRBC extract (Fig. S1) was 
analyzed in a 2D-PAGE/Western blot and the area containing the two spots detected by BM1234 
(Fig. S2A) was excised from an identical 2D-PAGE run in parallel (Fig. S2C) and subjected to LC-
MS/MS analysis (data not shown). The resulting peptides indicated that the BM1234 antigen was 
the membrane-associated histidine-rich protein 1 (MAHRP1), found in two major isoforms as 
previously described [39]. Subcellular fractionation analysis along the intraerythrocytic P. 
falciparum cycle (Fig. S3) confirmed the presence of the antigen mostly within insoluble membrane
fractions of the late stages trophozoites and schizonts, in agreement with the expected preferential 
localization of the protein in Maurer’s clefts [40], organelles involved in trafficking of several 
proteins towards the pRBC membrane [16,41]. Despite the intracellular location of MAHRP1, the 
improved pRBC targeting of BM1234 iLPs over LPs [10] suggested that at some time the 
recognized antigen should be exposed on the pRBC membrane. Indeed, MAHRP1 had been 
described as being essential for the translocation to the pRBC surface of PfEMP1, a mediator of 
pRBC cytoadherence to cell membrane receptors [42]. The association between these two proteins 
in pRBC plasma membrane regions has been confirmed by confocal fluorescence microscopy (Fig. 
S4). Consistent with these observations, TEM data showed the expected preferential intracellular 
localization of the BM1234 antigen, but with some occasional host cell plasma membrane-
associated signal (Fig. S5). Since MAHRP1 was suggested to bind erythrocytes through a 20-mer-
long amino acid region [43], we decided to generate polyclonal antibodies against this peptide 
(ADVPTEGMDVPFGFFDKNTL). As expected, the antigen detected by the resulting antibodies, 
MAHRP121-40, showed a subcellular localization similar to that of the BM1234 antigen (Figs. S6 and
S7).
Knowing the preferential intracellular localization of MAHRP1, we explored other protein 
targets present on pRBC surfaces for which commercial antibodies were available: Histidine-rich 
protein 2 (HRP2) [44] and glycophorin A (GPA) [45]. HRP2 is expressed during most of the P. 
falciparum life cycle (Fig. S3) and secreted by pRBCs, being therefore at some point present on the 
extracellular side of the plasma membrane (Figs. S8 and S9). GPA is a conserved and highly 
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abundant membrane protein present in all RBCs and pRBCs (Fig. 4A). To test the targeting capacity
of the selected antibodies, these were incubated with live pRBC cultures and analyzed directly 
without fixation by flow cytometry (Fig. 4B) and by fluorescence microscopy (Figs. 4C and S10). 
In these conditions, anti-GPA proved to be the only antibody capable of completely recognizing the 
entire RBC and pRBC populations, whereas BM1234, anti-HRP2, and anti-MAHRP121-40 bound just
a small fraction of pRBCs (<1%), in agreement with the different extracellular exposures of the 
respective antigens.
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Fig. 4. Cell targeting analysis of monoclonal anti-GPA antibody. (A) Immuno-TEM subcellular localization 
analysis in RBCs and in pRBCs at the ring, trophozoite, and schizont stages of erythrocytic glycophorin A. o:
outside of the cell; e: erythrocyte cytoplasm; p: P. falciparum. (B) Flow cytometry analysis of the binding of 
targeting antibodies to non-fixed RBCs and pRBCs. (C) Epifluorescence microscopic analysis of the binding 
of anti-GPA to live RBCs and pRBCs. Arrowheads indicate the three pRBCs present in the image.
3.3. Binding of targeting antibodies to LPs
The capacity of the antibodies raised against MAHRP1 (BM1234 and anti-MAHRP121-40), 
HRP2, and GPA as targeting agents for the functionalization of iLPs (DOPC:cholesterol:MPB-PE, 
65:20:15) was tested in vitro with live cells by fluorescence microscopy. iLPs containing in their 
formulation 0.5% of the rhodamine-labeled lipid DOPE-Rho, and loaded with 30 mM pyranine for 
tracking purposes, were subsequently functionalized with free thiol-bearing half-antibodies by 
crosslinking these to lipids containing thiol-reacting maleimide (Mal) groups as previously 
described [10] (Fig. S11). Consistently with the results obtained using free antibodies, of the four 
LP-Mal-antibody (LP-Mal-Ab), only anti-GPA iLPs were capable of completely recognizing target 
cells in live pRBC cultures (Fig. S12), though only at the high LP concentration of 1 mM total lipid.
In an attempt to improve anti-GPA-iLP targeting, three alternative iLP models were designed (Fig. 
5). A lipid bearing a 2-kDa polyethylene glycol (PEG) linker terminated with a Mal group (DSPE-
PEG-Mal) was included in the LP formulation (5% of total lipid; LP-PEG-Mal) with the double 
objective of (i) providing better antigen access to targeting Abs and (ii) improving the coupling 
reaction otherwise sterically hindered in the original iLP model by the polar heads of surrounding 
lipids [46,47]. This strategy was used for the oriented binding of half-antibodies through their free 
thiols (LP-PEG-Mal-Ab) or of whole antibodies through the carbohydrate moieties in antibody Fc 
regions (LP-PEG-Mal-CHO-Ab), and for the non-oriented binding through primary amino groups 
on Ab amino acid residues (LP-PEG-Mal-NH2-Ab). To support a pH gradient required for the active
encapsulation of amphiphilic drugs, the LP formulation was adapted by including the saturated lipid
DSPC and lowering the cholesterol content. The relative amounts of Mal-conjugated lipid and 
antibody were adjusted to a lipid:Ab 75-fold molar excess during coupling to maximize binding 
yield, with a final lipid composition DSPC:cholesterol:DSPE-PEG-Mal 85:10:5. Analysis of anti-
GPA iLPs showed that all four methods resulted in good coupling efficiencies above 30% of total 
antibody added (≥55 Ab molecules/LP), with LP-PEG-Mal-NH2-Ab showing the best results (Fig. 6
and Table 2). Protein smears observed in the gel lanes corresponding to samples coupled through 
primary amines indicate an efficient incorporation of maleimide-containing lipids and SATA 
crosslinker molecules, which decreased the electrophoretic mobility of antibody chains.
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Fig. 5. Representation of iLP models encapsulating an amphiphilic weak basic drug and functionalized with 
antibodies linked through four different conjugation strategies, all based on the formation of a thioether bond
between a thiolated antibody and a maleimide-conjugated lipid. For cell targeting assays, drugs were 
substituted by the fluorescent dye pyranine as a tracker for the LP aqueous core and a rhodamine-conjugated 
lipid (DOPE-Rho) was included in the LP formulation. LP-Mal-Ab and LP-PEG-Mal-Ab: half-antibody is 
conjugated in oriented position, in the second model at the distal end of a 2-kDa PEG linker. LP-PEG-Mal-
CHO-Ab: whole antibodies are conjugated in oriented position through the carbohydrate chains in the Fc 
region. LP-PEG-Mal-NH2-Ab: whole antibodies are conjugated in non-oriented position through primary 
amino groups, which in some cases can be placed within the antigen binding site, interfering with antigen 
recognition (arrowhead). In the first model the drug is represented as being passively loaded, whereas the 
other three models represent drug actively loaded with the pH gradient method.
Fig. 6. Silver-stained, reducing SDS-PAGE analysis of different strategies for the coupling of anti-GPA 
polyclonal antibodies to LPs. Coupling was via a PEG-Mal linker through: (Half-Ab) the free thiol of half-
antibodies, LP-PEG-Mal-Ab model; (Fc-CHO) the carbohydrate moiety in Fc regions, LP-PEG-Mal-CHO-
Ab model; (NH2) primary amino groups with different amounts of the crosslinking agent SATA (10 and 
100 molar excess relative to antibody molecules), LP-PEG-Mal-NH2-Ab model. Prior to electrophoresis, 
samples containing 2 µg protein were centrifuged for the analysis of LP-bound antibodies in the pellet (B) 
and of unbound antibodies in the supernatant (U). The ca. 70-kDa band with a relatively minor incorporation 
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into LPs when compared to the ca. 55-kDa band of IgG heavy chains, corresponds to rabbit albumin, which 
is highly abundant in animal serum and interacts with Protein G during IgG purification [48]. When using 
monoclonal antibodies, albumin is absent (Fig. S13). The fluorescence emission of rhodamine (Rho) 
conjugated to lipids included in the formulation of LPs, and of pyranine dye (Pyr) with which they were 
passively loaded, are used as controls of the LP-containing fractions.
Table 2. Characterization of the different methods used to conjugate the polyclonal anti-GPA antibody to 
maleimide-PEG-grafted LPs (LP-PEG-Mal model).
Parameter Half-Ab Fc-CHO NH2 10 SATA NH2 100 SATA
Sulfhydryl groups / Ab 0.7 ± 0.4 1.9 ± 0.5 2.9 ± 0.4 10.2 ± 0.1
Coupling efficiency (%) 32.5 ± 5.0 39.6 ± 2.2 44.1 ± 1.5 54.4 ± 0.0
µg Ab / µmol lipid 34.6 ± 5.3 32.1 ± 1.8 53.3 ± 1.8 67.1 ± 0.0
Ab number per LP 55.6 ± 8.5 51.6 ± 2.8 85.6 ± 2.8 107.6 ± 0.0
Size increment (nm) 4.9 ± 3.4 0.0 ± 4.4 8.7 ± 3.3 17.1 ± 1.3
3.4. Cell targeting of iLPs
Flow cytometry studies on non-fixed RBCs using the different iLP models indicated a cell 
targeting efficiency LP-PEG-Mal-NH2-Ab >> LP-PEG-Mal-CHO-Ab >> LP-Mal-Ab/LP-PEG-
Mal-Ab (Fig. 7A). After a 30-min incubation, only ca. 10% of cells were bound by LP-Mal-Ab anti-
GPA iLPs at 250 µM lipid in culture, whereas LP-PEG-Mal-NH2-Ab generated using the relatively 
low crosslinker:Ab 10 molar excess resulted in ~100% cell targeting at a concentration of 100 µM 
lipid. This complete targeting could be maintained when using a monoclonal anti-GPA (LP-PEG-
Mal-NH2-MAb-10) even at a LP concentration of 50 µM lipid, and down to 0.5 µM lipid 
according to fluorescence microscopy analysis (Fig. S14). Cryo-TEM images showed that >90% of 
LPs in this last model carried antibodies (Fig. S15), result consistent with the observation that >80%
of LPs are retained on target cells at 50 µM lipid, whereas retention values were below 15% for all
other iLP models (Fig. 7B). It is important to note that using a 10-fold increase of the chemical 
crosslinker SATA (100 molar excess) inhibited cell targeting (Fig. 7), likely due to massive 
crosslinking of NH2 groups near the antigen recognition site of antibodies. When LP-PEG-Mal-
NH2-MAb-10 iLPs were incubated with live pRBC cultures for 90 min, confocal fluorescence 
microscopy analysis showed colocalization of rhodamine and pyranine signals on RBCs and pRBCs
as a punctate pattern (Fig. 8A-C). This suggested that erythrocyte-bound iLPs did not immediately 
fuse with the plasma membrane, but rather remained adsorbed onto the cell. The observation of the 
presence of diffuse fluorescence areas in some RBCs (Fig. 8B), but especially on pRBCs (Fig. 8C), 
suggests that eventually iLPs could fuse with the cell, despite the lipid formulation used here 
(dominated by saturated lipids) significantly inhibits such fusion events. Free pyranine controls 
showed passive entry of this highly hydrophilic dye only into pRBCs (Fig. 8D).
Fig. 7. RBC targeting analysis after a 30-min incubation with anti-GPA iLPs loaded with 30 mM pyranine 
and prepared through different antibody conjugation methods. (A) Flow cytometry results showing the 
fraction of RBCs positive for pyranine signal. (B) Determination by pyranine fluorescence quantification in 
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the culture supernatant of the iLP fraction bound to cells. All samples were prepared with polyclonal 
antibodies except LP-PEG-Mal-NH2-MAb-10, where a monoclonal antibody was used.
Fig. 8. Fluorescence microscopy analysis of the interaction of anti-GPA iLPs with target cells. Rhodamine-
labeled anti-GPA LP-PEG-Mal-NH2-Ab iLPs loaded with pyranine (concentrations in the culture of 500 µM 
lipid and 26 µM pyranine) were added to live pRBC cultures, incubated for 90 min and visualized without 
fixation by (A) confocal fluorescence microscopy and (B, RBC; C, pRBC) epifluorescence microscopy. The 
arrowheads indicate diffuse fluorescence areas. (D) Control sample where 26 µM free pyranine was added to
the culture.
3.5. P. falciparum growth inhibition activity of anti-GPA iLPs encapsulating antimalarial drugs
The iLP prototype having both best targeting efficiency and retention into pRBC cultures (LP-
PEG-Mal-NH2-MAb-10 functionalized with monoclonal antibodies against human GPA) was 
selected for in vitro growth inhibition assays of P. falciparum. Drug concentrations during active 
encapsulation of 500 µM CQ and 1 mM PQ (for 10 mM total lipid) were selected to avoid an 
excessive consumption of the LP internal proton pool and subsequent disruption of the liposomal 
pH gradient [21,35], yielding EEs of 98.3 and 96.7% for CQ and PQ, respectively (Table 1). After 
only 15 min of incubation in the presence of iLPs, pRBC cultures were washed and incubated for a 
further 48 h (one replication cycle). CQ activity significantly improved when actively encapsulated 
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into iLPs, with an IC50 of ca. 35 nM when administered to P. falciparum cultures synchronized in 
either ring or late blood stages (trophozoites + schizonts), whereas at a concentration of 50 nM 
encapsulated CQ, parasite growth was completely inhibited (Fig. 9A,B). In contrast, free CQ was 
only capable of completely inhibiting Plasmodium growth when added to late forms at a 
concentration in culture of 200 nM, although this dose was ineffective when added to ring stages. 
Neither agglutination nor morphological alterations of RBCs were observed upon microscopic 
examination of Giemsa-stained slides from growth inhibition assays (Fig. S16). Fluorescence 
microscopy and flow cytometry analysis (Fig. S17), as well as hemolysis assays (Fig. S18), further 
confirmed an absence of adverse effects on non-infected RBCs within the liposome molar range 
leading to complete P. falciparum growth inhibition (1-4 µM lipid, corresponding respectively to 
ca. 19-75 iLPs/RBC; Fig. S19), indicating that erythrocyte viability was not compromised by iLP 
binding. When ≥50 nM CQ encapsulated in iLPs was added at ring stage, the parasites were killed 
before completing their intraerythrocytic cycle, as evidenced by a lack of increase in pRBC 
numbers after 48 h and the microscopic observation of picnotic Plasmodium nuclei indicative of 
cell death (Fig. S16A). On the other hand, when added to late stages, treated parasites egressed from
pRBCs but had a low invasion rate and those which could invade RBCs failed to mature into late 
forms, dying at ring stage. Again, this growth inhibitory effect was evidenced by pRBC counts and 
microscopic examination (Fig. S16B). Fluorescence microscopy detection at the end of growth 
inhibition assays of DOPE-Rho lipid that had been incorporated into the LP formulation confirmed 
the expected iLP binding to all RBCs and pRBCs (Fig. S20). In late forms, lipid fluorescence was 
often observed to be homogeneously distributed throughout the cell, hinting at LP fusion with the 
pRBC membrane during the length of 48-h growth inhibition assays. Dramatic activity increases 
were also obtained for actively encapsulated PQ, which at 10 µM eliminated parasitemia almost 
completely in both ring and late form cultures, whereas the same concentration of free drug did not 
have any significant effect on the parasite (Fig. 9C). However, PQ-containing iLPs had in vitro an 
RBC agglutinating effect (Fig. 9D-F), likely due to the need to add a large amount of drug-
encapsulating LPs (50-100 µM lipid, corresponding respectively to 940-1,880 iLPs/RBC; Fig. S19) 
because of the high in vitro IC50 of PQ, which is in the µM range. This agglutinating effect was 
especially significant under static incubation conditions for high iLP amounts >10 µM lipid (Figs. 
S17 and S19). Absence of hemolysis was observed even for the highest agglutinating iLP amount of
100 µM lipid (Fig. S18).
Preliminary in vivo 4-day tests in mice grafted with human erythrocytes and subsequently 
infected with P. falciparum showed that anti-GPA iLPs (LP-PEG-Mal-NH2-MAb-10) 
encapsulating CQ cleared the pathogen below detectable levels (<0.01% parasitemia in peripheral 
blood) at a CQ dose of 0.5 mg/kg, whereas free CQ administered at 1.75 mg/kg was, at most, 40-
fold less efficient (ca. 0.4% parasitemia; Fig. 10). 0.5 mg CQ/kg administered in non-targeted 
liposomes had a much diminished effect, which highlights the crucial role of GPA targeting. The 
survival of iLP-treated mice suggests that the function of non-infected RBCs was not significantly 
affected in vivo by CQ-loaded iLPs at the concentration required to eliminate parasitemia from 
infected animals.
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Fig. 9. P. falciparum growth inhibition assays of the effect of CQ and PQ as free drugs and encapsulated in 
LPs and iLPs. CQ (A, B) and PQ (C) encapsulated in LP-PEG-Mal-NH2-Mab anti-GPA iLPs, in LP-PEG-
Mal LPs, or in non-encapsulated form were added at the same final concentrations to either ring or late blood
stages (trophozoites and schizonts) and let to act for 15 min before removing them by changing the 
incubation medium. After a further 48 h incubation the samples were analysed by flow cytometry to 
determine P. falciparum growth. For PQ samples are shown images of cultures treated with free PQ (D), iLP-
PQ (E), and LP-PQ (F), to show agglutination in the iLP-treated samples. Highest LP concentrations in P. 
falciparum cultures were 100 µM and 4 µM lipid for 10 µM PQ and 200 nM CQ, respectively.
Fig. 10. 4-day test in female immunodeficient mice engrafted with human RBCs and infected i.v. with P. 
falciparum. The animals were treated with the indicated drug preparations at days 3 to 6 after infection. The 
anti-GPA-iLP+CQ sample contained 48 mmol CQ/mol lipid, whose administered dose corresponded to ca. 
100 iLP/erythrocyte, assuming 11010 human RBCs in the mouse blood circulation.
4. Discussion
Plasmodium early stages are ideal therapeutic targets because drugs delivered to them would 
have a longer time to kill the parasite before it completes its development, although the permeability
of the infected erythrocyte to ions and small nonelectrolytes, including some drugs, does not 
increase until ca. six hours after invasion [17]. During its maturation the parasite hydrolyzes 
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hemoglobin in a digestive vacuole, which is the target of many amphiphilic drugs that freely cross 
the RBC membrane and accumulate intracellularly. As a result, most antimalarials start affecting the
infected cell relatively late in the intraerythrocytic parasite life cycle, when their effect is probably 
often too short to be lethal for Plasmodium.
A strategy to improve the activity of antimalarial drugs contemplates their encapsulation in 
nanocarriers specifically targeted to pRBCs [49], which requires the existence of specific pRBC 
markers. 200-nm LPs studded with heparin or specific antibodies raised against pRBCs have been 
shown to bind late stages with high specificity [10,50], increasing up to tenfold the efficacy of 
encapsulated antimalarial drugs in vitro [12,50]. However, the therapeutic administration of such 
liposomal models against late stages has to be timed to the precise moment when trophozoites and 
schizonts are present in blood, between 24 and 48 h into the P. falciparum intraerythrocytic cycle. 
The relatively short blood half-life of, in the best case, <10 h for polyethylene glycol-coated stealth 
LPs [51], guarantees that if injected when early stage pRBCs are present, by the time late forms 
mature most LPs will have been removed from the blood circulation. Polymeric nanovectors were 
observed to penetrate trophozoites and schizonts [30], most likely through the TVN, although entry 
of nanoparticles into early ring stages has not been observed so far for P. falciparum or any other 
human malaria species. As an additional obstacle to antimalarial targeted delivery strategies, most 
externally recognizable pRBC proteins are present in the parasite genome as multiple variants that 
can be clonally expressed [15]. In vitro, the targeting of pRBCs using laboratory strains of 
Plasmodium that present known, homogeneously expressed antigens is a valid approach allowing 
for the use of the corresponding antibody specific for each particular target molecule, but in a 
clinical setting this strategy is invalidated by the large clonal variability inherent to a typical malaria
infection.
Malaria is a systemic infection of erythrocytes, where targeted drug delivery approaches are 
complicated by the fluidics conditions found in the blood circulation, whose strong flow drag and 
shear forces necessarily affect the interaction of molecular components with target cells. In this 
adverse physical environment, the design of iLPs engineered to encapsulate antimalarial drugs for 
their specific entry into pRBCs has to be especially careful regarding the liposomal nanocapsule 
composition, which will define drug encapsulation and partition within the vesicle, and the selection
of targeting antibody/antigen pairs. Although the oriented binding of half-antibodies through their 
free thiols or of whole antibodies through their carbohydrate moieties in the Fc region is a priori a 
guarantee to increase antigen binding site exposure and thus target binding efficiency, our results 
indicate that non-oriented binding through primary amino groups significantly increases the number
of antibodies bound per LP, whereas carefully choosing the amount of chemical crosslinker used 
preserves a high antigen binding capacity, at least for the monoclonal anti-GPA antibody used here. 
Considering the limitations exposed above for an efficient pRBC targeting, efforts have to be 
invested in encapsulating the highest drug cargo possible. Using the pH gradient active loading 
method [36] and LP formulations high in saturated lipids capable of sustaining a proton gradient, 
we have obtained for the weak basic drugs CQ and PQ encapsulation efficiencies close to 100% and
high intraliposomal retention levels >95% for several hours in both storage and culture conditions. 
However, the varied physicochemical properties of present and future antimalarial drugs will 
determine their location within the liposomal structure [52,53], calling for encapsulation strategies 
adapted to each particular compound.
Antimalarial drug carriers should provide optimal drug half-lives in circulation, adequate 
clearance mechanisms, restriction of unintended drug effects in non-target cells, specific delivery to 
the correct tissue, and a timely initiation and termination of the therapeutic action. Considering the 
interest in targeting intraerythrocytic Plasmodium as early in its life cycle as possible and the lack 
of strategies to shuttle drugs into it, alternative approaches must be explored without 
preconceptions. A way to overcome the aforementioned exposed obstacles to the design of pRBC-
targeted nanocarriers can perhaps be provided by one of the most adequate vascular carriers ever 
proposed; namely, red blood cells themselves [54]. Human erythrocytes have a life span in the 
blood of up to 120 days, which makes them attractive carriers for intravascular delivery because 
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they prolong drug circulation. In addition, their large size (ca. 7 µm across and around 2 µm thick) 
significantly restricts unintended extravasation and in principle allows for a much larger 
encapsulation capacity than LPs. Other interesting features of RBCs as drug carriers are their 
biocompatibility and the existence of natural mechanisms for their safe elimination from the body. 
Actually, delivery of antimalarials to non-infected red blood cells to study the effects on later 
invading parasites has been an approach used for chemotherapeutic investigations, where 
pretreatment of erythrocytes with the drugs halofantrine, lumefantrine, piperaquine, amodiaquine, 
and mefloquine showed that these diffuse into and remain within the cell, inhibiting downstream 
growth of Plasmodium [55]. Nevertheless, the loading of drugs into non-infected RBCs has not yet 
been explored in detail as a clinically feasible therapeutic strategy against malaria, since most 
currently available protocols use a harsh ex vivo erythrocyte isolation followed by drug loading 
through diffusion [54].
RBC-targeted iLPs could be used to shuttle into the cell antimalarial drugs, although the 
incapacity of mature erythrocytes to endocyte [56] calls for the development of specific targeted 
delivery strategies independent from the receptor-mediated endocytic pathway. Delivery of iLP 
cargo into RBCs had been proposed to occur through membrane fusion [7], a highly controlled 
process that requires the incorporation of specific fusogenic agents into the lipid bilayer [57,58]. 
Nevertheless, because of little evidence for liposomal fusion observed with RBCs, alternative routes
for the incorporation of LP contents into targeted erythrocytes should be examined [53]. The TVN 
induced by Plasmodium during its intraerythrocytic growth [17] extends from the parasitophorous 
vacuole membrane and connects the intracellular parasite with the host RBC surface. However, this 
confers to the pRBC the capacity of internalizing a wide range of particles up to diameters of only 
70 nm [17,59], well below the mean size of the LPs used here. Other potential mechanisms to 
consider include LP adsorption on the cell surface followed by either the exchange of hydrophobic 
molecules (e.g. the antimalarial drugs lumefantrine and halofantrine) between apposed lipid bilayers
[60,61], or a sustained release of the entrapped material [53]. This process would be mediated by a 
depletion of the liposomal proton gradient by means of temperature, LP-cell interaction events [62] 
and lipid sequestration by plasma components [63], and might be highly effective for the delivery of
weak basic drugs such as those from the aminoquinoline family. These compounds, positively 
charged at acidic/neutral pH, will theoretically accumulate inside the cell by virtue of the 
electrochemical gradient created by the phospholipid asymmetry in RBC membranes [64], which 
maintains a negatively charged intracellular membrane lining. Although the slow drug release 
observed for pH gradient-loaded LPs is a requirement for storage periods and to avoid drug leaking 
before reaching their target, once docked to pRBCs liposomal contents must enter the cell. Here, we
have observed for CQ a similar in vitro IC50 when present either for 48 h as free drug or for only 15
min encapsulated in iLPs, suggesting an adequate drug transfer from iLP to cell.
Other foreseeable limitations to targeting RBCs as an antimalarial strategy will have to be 
considered. First, to avoid erythrocyte agglutination, an upper iLP concentration threshold must be 
established in vivo, which will complicate the application of this model to drugs with a high IC50. 
In this regard, according to the data reported here for drugs having a low IC50 like CQ, a ratio of 
ca. 100 iLP/RBC (lacking agglutination and hemolysis activity in vitro) led in mice grafted with 
human erythrocytes to complete elimination of parasitemia. A second requirement for the use of 
RBCs as antimalarial carriers is that when present at therapeutically active concentration, the drug 
has to be innocuous for the cell physiology, which might not be an unsurmountable obstacle given 
the reduced metabolic activity of erythrocytes. However, loading of some antimalarial drugs like 
clotrimazole had been observed to predispose RBCs to oxidative damage [65], an undesirable 
scenario since oxidized RBCs are rapidly taken up by hepatic reticuloendothelial system 
macrophages. Finally, because LPs adsorbed on RBC surfaces would probably sufficiently modify 
cell shape to target it for removal through spleen filtration, a compromise between stable drug 
containment and lipid bilayer fusion might have to be reached through the adequate LP formulation,




Antigens found in all RBCs can be a target to consider for antimalarial drug delivery, trading 
pRBC specificity for a far larger abundance of anchoring points on the cell surface. Because the 
selected RBC markers are also found on pRBCs, targeted iLPs would have a double activity as 
therapeutic and prophylactic agents when simultaneously delivering drug to, respectively, infected 
and non-infected cells. It is reasonable to predict that the nanovector design limitations exposed 
above can be satisfactorily dealt with, and that some of the future antimalarials yet to be discovered 
will be harmless for erythrocytes, thus allowing for the loading into them of drug amounts being 
lethal for Plasmodium. If so, the pathogen might encounter its enemy at home, right at the very 
moment of entering the host cell, which would have devastating effects for the parasite and 
significantly compromise its survival capacity.
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